Streetbeat News

Analyst Ratings

HCAT

RBC Capital analyst Sean Dodge has maintained a 'Sector Perform' rating on Health Catalyst (NASDAQ:HCAT) but lowered the price target from $13 to $8.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:46 pm

COST

A 'whale' investor has taken a bullish stance on Costco Wholesale (NASDAQ:COST), with 50% of investors opening trades with bullish expectations and 50% with bearish. The whale trades have targeted a price range from $535.0 to $580.0 for Costco over the last 3 months. Telsey Advisory Group has maintained their Outperform rating on Costco, with a price target of $600. Truist Securities downgraded its action to Buy with a price target of $619.

Portfolio Pulse from Benzinga Insights

October 30, 2023 | 5:45 pm

IDXX

Benzinga's options scanner detected over 10 options trades for IDEXX Laboratories (NASDAQ:IDXX) totaling $490,784. Whales have been targeting a price range from $360.0 to $410.0 for IDEXX Laboratories over the last 3 months. The price of IDXX is up 1.29% at $396.43. Stifel has decided to maintain their Hold rating on IDEXX Laboratories, which currently sits at a price target of $460.

Portfolio Pulse from Benzinga Insights

October 30, 2023 | 5:45 pm

GLPI

RBC Capital analyst Brad Heffern maintains an 'Outperform' rating on Gaming and Leisure Properties (GLPI), but has lowered the price target from $54 to $50.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:44 pm

ESS

RBC Capital analyst Brad Heffern maintains an 'Outperform' rating on Essex Property Trust (NYSE:ESS) but lowers the price target from $241 to $235.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:43 pm

PTGX

Capital One analyst Tim Chiang has initiated coverage on Protagonist Therapeutics (NASDAQ:PTGX) with an Overweight rating.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:41 pm

CTVA

RBC Capital analyst Arun Viswanathan has maintained an 'Outperform' rating on Corteva (NYSE:CTVA), but lowered the price target from $67 to $61.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:38 pm

CYH

RBC Capital analyst Ben Hendrix maintains an 'Outperform' rating on Community Health Sys (NYSE:CYH) but lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:37 pm

CL

RBC Capital analyst Nik Modi has maintained a 'Sector Perform' rating on Colgate-Palmolive (NYSE:CL) and raised the price target from $79 to $80.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 5:33 pm

VYNE

VYNE Therapeutics released new preclinical data showing positive effects of its VYN202 in preclinical models of psoriasis and rheumatoid arthritis. The company plans to submit its IND for VYN202 by the end of 2023 and start Phase 1a trials in Q1 2024. If successful, Phase 1b trials will commence in H2 2024. VYNE also announced private placement financing of $88 million. HC Wainwright maintains a Buy rating for VYNE but reduced the price target to $5.75 from $28 due to dilution from the equity and warrant raise.

Portfolio Pulse from Vandana Singh

October 30, 2023 | 5:29 pm